Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%78 3-Year EBITDA Growth Rate is -6.90% as of Dec. 2025. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 104 Medical Distribution companies, Sinopharm Group Co ranks worse than 76.92% on this metric.
During the past 12 months, Sinopharm Group Co's average EBITDA Per Share Growth Rate was 3.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -6.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -4.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sinopharm Group Co was 61.50% per year. The lowest was -8.90% per year. And the median was 14.50% per year.
Sinopharm Group Co (OTCPK:SHTDF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sinopharm Group Co 3-Year EBITDA Growth Rate Related Terms
SHTDF vs MCK, CAH, COR: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's 3-Year EBITDA Growth Rate falls into.
Sinopharm Group Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -6.90% mean?
Sinopharm Group Co (SHTDF) has a 3-Year EBITDA Growth Rate of -6.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sinopharm Group Co and its competitors. According to the industry distribution chart, Sinopharm Group Co ranks #80 out of 104 companies in the Medical Distribution industry, placing it in the top 76.9%.
Is Sinopharm Group Co's 3-Year EBITDA Growth Rate too high?
Sinopharm Group Co's current 3-Year EBITDA Growth Rate is -6.90%. Based on the distribution chart, Sinopharm Group Co ranks #80 out of 104 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's 3-Year EBITDA Growth Rate compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #80 out of 104 companies for 3-Year EBITDA Growth Rate. This places Sinopharm Group Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 6.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 6.10, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 6.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current 3-Year EBITDA Growth Rate is -6.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.58, compared to a current price of $2.13 — trading 17.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -6.90%. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current 3-Year EBITDA Growth Rate is -6.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 17.3% below its estimated GF Value™ of $2.58.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
3-Year EBITDA Growth Rate: -6.90%
GF Value™: $2.58 vs. price of $2.13 (17.3% below fair value)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
